Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease

14. juli 2011 opdateret af: Eisai Co., Ltd.

A Double-Blind, Placebo-Controlled, Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease

To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind, comparative study.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

288

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Japan
    • Aichi-Prefecture
      • Aichi-Gun, Aichi-Prefecture, Japan, 480-1103
      • Nagoya, Aichi-Prefecture, Japan, 467-0001
      • Nagoya, Aichi-Prefecture, Japan, 466-0065
    • Fukuoka-Prefecture
      • Chikushino, Fukuoka-Prefecture, Japan, 818-0024
      • Chikushino, Fukuoka-Prefecture, Japan, 818-0067
      • Fukuoka, Fukuoka-Prefecture, Japan, 813-0003
      • Kita-kyushu, Fukuoka-Prefecture, Japan, 807-1262
    • Gunma-Prefecture
      • Maebashi, Gunma-Prefecture, Japan, 371-0034
    • Hiroshima-Prefecture
      • Hiroshima, Hiroshima-Prefecture, Japan, 734-0037
      • Hiroshima, Hiroshima-Prefecture, Japan, 730-0052
    • Hokkaido-Prefecture
      • Sapporo, Hokkaido-Prefecture, Japan, 003-0021
      • Sapporo, Hokkaido-Prefecture, Japan, 060-0061
      • Sapporo, Hokkaido-Prefecture, Japan, 060-0814
    • Kochi-Prefecture
      • Kochi, Kochi-Prefecture, Japan, 780-0901
    • Kyoto-Prefecture
      • Kyoto, Kyoto-Prefecture, Japan, 602-0000
      • Kyoto, Kyoto-Prefecture, Japan, 606-8397
    • Miyagi-Prefecture
      • Sandai, Miyagi-Prefecture, Japan, 980-0872
      • Sendai, Miyagi-Prefecture, Japan, 984-0075
    • Osaka-Prefecture
      • Moriguchi, Osaka-Prefecture, Japan, 570-0021
      • Osaka, Osaka-Prefecture, Japan, 530-0012
      • Osaka, Osaka-Prefecture, Japan, 545-0051
      • Osaka, Osaka-Prefecture, Japan, 536-0002
    • Saga-Prefecture
      • Saga, Saga-Prefecture, Japan, 849-0937
    • Saitama-Prefecture
      • Kawaguchi, Saitama-Prefecture, Japan, 332-0021
    • Shimane-Prefecture
      • Izumo, Shimane-Prefecture, Japan, 693-0021
      • Matsue, Shimane-Prefecture, Japan, 690-0886
    • Shizuoka-Prefecture
      • Hamamatsu, Shizuoka-Prefecture, Japan, 431-3125
    • Tokyo
      • Shinagawa-ku, Tokyo, Japan, 140-0011
      • Shinjuku-ku, Tokyo, Japan, 162-0052
    • Yamaguchi-Prefecture
      • Sanyoonoda, Yamaguchi-Prefecture, Japan, 756-0076
      • Sanyoonoda, Yamaguchi-Prefecture, Japan, 757-0002
      • Ube, Yamaguchi-Prefecture, Japan, 755-0046
      • Ube, Yamaguchi-Prefecture, Japan, 755-0004
      • Ube, Yamaguchi-Prefecture, Japan, 755-0067
      • Ube, Yamaguchi-Prefecture, Japan, 755-0077

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

The patients to be included will be outpatients who meet all of the following criteria. No specific gender is asked.

<For the observation period>

  1. Patients who have "heartburn" 2 days a week or more for consecutive weeks during 3 weeks prior to pre-observation screening. If a day of screening and a day of starting observation (date of registration) are different, heartburn must continuously be present during the in-between period.
  2. Patients who meet both 1) and 2) below; 1) The symptom is a burning sensation arising from the stomach or the lower chest.

2) The symptom tends to appear frequently or is aggravated after eating, when bending a body forward, and/or when pressing on the abdomen.

(3) Patients categorized in "grade M" (discoloring type: minimal change) according to the Los Angeles System (2nd Modification) for Classification of Reflux Esophagitis.

(4) Patients who are 20 years old or older at the time of obtaining consent. (5) Patients who are informed of the objective and details of the study and give written consent for study entry.

<For the treatment period>

  1. Patients who have "heartburn" on 2 days a week or more in 7 days immediately before the treatment period (during the observation period).
  2. Patients with "heartburn diary" that is completely filled out for 7 days until the treatment period (during the observation period). If the observation period is 8 days or longer, those with heartburn diary of which entries are fulfilled 80% or more during the observation period.
  3. Patients with 80% or better drug compliance for antacids during the observation period.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. Patients who cannot keep adequate entries of heartburn diary by themselves.
  2. Patients who strongly complain "feeling of heavy stomach" and/or "abdominal bloating."
  3. Patients who have a complication or history of psychiatric or psychosomatic disease (e.g., manic-depressive psychosis, obsessive-compulsive neurosis, or others) or those who are on an antidepressant or anti-anxiety agent (accepted if only for a hypnotic treatment).
  4. Patients who have undergone Helicobacter pylori eradication therapy, and less than 6 months have elapsed from the end of H. pylori eradication therapy to the beginning of the observation period. : The same day 6 months earlier, and the day at the end of 6 months earlier if it is at the end of month.
  5. Patients with open gastric or duodenal ulcer.
  6. Patients with acute gastritis.
  7. Patients with a history of any surgical intervention that affect peptic secretion (e.g., upper gastrointestinal tract resection and/or vagotomy).
  8. Patients with Barrett's esophagus, esophageal stenosis, or pyloric stenosis.
  9. Patients with scleroderma.
  10. Patients with a history or complication of angina pectoris.
  11. Patients who work at night (working for a night-shift).
  12. Patients who received proton pump inhibitors (PPIs) within 3 weeks prior to pre-observation screening
  13. Patients who need NSAIDs (except topical preparations), steroids (except topical preparations), and/or aspirin treatment every day
  14. Patients receiving dialysis therapy
  15. Patients with a serious complication such as cardiovascular disease (e.g., myocardial infarction), hematological disorder (e.g., aplastic anemia), renal disease (e.g., acute or chronic renal failure), hepatic disease (e.g., cirrhosis), or malignant tumor.
  16. Patients with known hypersensitivity to antacids or PPIs.
  17. Patients who are pregnant or those with childbearing potential, or those who wish to become pregnant or are lactating during the study period.
  18. Patients receiving another investigational drug or those who received another investigational drug within 6 months prior to pre-observation screening : Registration is allowed on the same day of 6 months earlier, and the day at the end of 6 months earlier if it is at the end of month.
  19. Patients who are judged to be ineligible for the study entry by the investigator or subinvestigator.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 1
Medicin: E3810
E3810 5mg: once daily orally for 4 weeks
Medicin: E3810
E3810 10mg: once daily orally for 4 weeks
Eksperimentel: 2
Medicin: E3810
E3810 5mg: once daily orally for 4 weeks
Medicin: E3810
E3810 10mg: once daily orally for 4 weeks
Placebo komparator: 3
Medicin: Placebo
Placebo: once daily orally for 4 weeks

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With Complete Relief of Heartburn at Final Evaluation
Tidsramme: 4 weeks
"Heartburn diary" will be given to each subject and ask him/her to keep the diary every day throughout the study period. The subject will be requested to record the occurrence of heartburn during the daytime and the nighttime in the diary. Primary End Point is the rate of complete disappearance of heartburn. The rate of heartburn do not occur in the past week will be calculated based on the diary. Participants were evaluated at week 4 about episodes of heartburn in the last 7 days
4 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Eisai Co., Ltd.

Efterforskere

  • Studieleder: Nobuyuki Sugisaki, Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2004

Primær færdiggørelse (Faktiske)

1. oktober 2005

Studieafslutning (Faktiske)

1. oktober 2005

Datoer for studieregistrering

Først indsendt

12. september 2005

Først indsendt, der opfyldte QC-kriterier

12. september 2005

Først opslået (Skøn)

14. september 2005

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

18. juli 2011

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. juli 2011

Sidst verificeret

1. august 2010

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • E3810-J081-461

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner